Distributor inventory | Tablet
Voglibose 0.2 mg + Repaglinide 1 mg tablet
Type 2 diabetes mellitus to improve post‑meal and overall blood glucose control when diet and exercise alone are insufficient; used when dual therapy is advised by the doctor.
Voglibose is an alpha‑glucosidase inhibitor that delays carbohydrate digestion and absorption in the intestine, reducing post‑meal glucose spikes. Repaglinide is a meglitinide that stimulates the pancreas to release insulin in a glucose‑dependent manner, mainly controlling post‑prandial blood sugar.
Oral tablet. Take exactly as prescribed. Generally taken just before meals (0–30 minutes before); if a meal is skipped, the dose is usually skipped to reduce hypoglycaemia risk. Follow diet/exercise advice and monitor blood glucose.
Common side effects of VOLIBO R 0.2/1MG TAB may include:
May cause hypoglycaemia (especially if you skip/delay meals, take with other antidiabetics, or drink alcohol); carry glucose source. Use caution in liver impairment; periodic liver function monitoring may be advised. Not recommended in type 1 diabetes or diabetic ketoacidosis. GI side effects (gas/diarrhoea) are common due to voglibose. Inform doctor about recurrent hypoglycaemia, heart disease, kidney/liver problems, or if you are elderly. Seek medical help for severe allergic reaction or persistent abdominal symptoms.
